Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug to reduce side effects of flunarizine hydrochloride to treat angioneurotic headache

A technology of flunarizine hydrochloride and side effects, applied in the field of drugs for treating angioneurotic headache, can solve problems such as susceptibility to depression and the like

Inactive Publication Date: 2018-12-25
LINYI DELIKANG MEDICAL REHABILITATION EQUIP CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, flunarizine hydrochloride capsules used in western medicine can expand the spasm blood vessels, slow and smooth blood flow, and improve vasomotor dysfunction, but side effects of drowsiness and fatigue often occur, and long-term use is prone to depression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug to reduce side effects of flunarizine hydrochloride to treat angioneurotic headache
  • Drug to reduce side effects of flunarizine hydrochloride to treat angioneurotic headache

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0008] Embodiment 1: The drug for reducing the side effects of flunarizine hydrochloride and treating vascular neuropathic headache consists of 9 g of flunarizine hydrochloride, 13 g of snakeroot extract, 60 g of lactose, 50 g of pregelatinized starch, and croscarmellose Made of 12g of sodium, 1g of magnesium stearate, 0.5g of micropowdered silica gel, and 18g of hydroxypropyl cellulose. Weigh flunarizine hydrochloride, snakeroot extract, lactose, pregelatinized starch, croscarmellose sodium, and hydroxypropyl cellulose, mix them evenly, add appropriate amount of water to make a soft material, granulate, Air blow drying, granulation, adding the prescribed amount of magnesium stearate and micronized silica gel, mixing evenly, and pressing into tablets.

Embodiment approach 2

[0009] Embodiment 2: The medicine for reducing the side effect of flunarizine hydrochloride and treating vascular neuropathic headache consists of 12g of flunarizine hydrochloride, 17g of snakeroot extract, 65g of lactose, 65g of pregelatinized starch, and croscarmellose It is made of 14g of sodium, 2g of magnesium stearate, 0.9g of micropowdered silica gel, and 21g of hydroxypropyl cellulose, and the preparation method is the same as the first embodiment.

Embodiment approach 3

[0010] Embodiment 3: The medicine for reducing the side effects of flunarizine hydrochloride and treating vascular neuropathic headache consists of 14 g of flunarizine hydrochloride, 21 g of snakeroot extract, 70 g of lactose, 80 g of pregelatinized starch, and croscarmellose It is made of 16g ​​of sodium, 3g of magnesium stearate, 1.2g of micropowdered silica gel, and 24g of hydroxypropyl cellulose, and the preparation method is the same as the first embodiment.

[0011] Quality inspection

[0012] It is produced according to the prescription process in the embodiment, and compared with the commercially available product (batch number 20110202). The results are shown in the table below.

[0013]

[0014] Accelerated test investigation

[0015] The finished product sealed with white plastic bottle is placed in an environment of 36±14°C and relative humidity (RH) 50%±25% for 6 months for stability inspection. The determination indicators include content, dissolution rate, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug to reduce side effects of flunarizine hydrochloride to treat angioneurotic headache and belongs to the technical field of drug application. Tests prove that the drug herein has stable and qualified indexes, such as content, dissolution rate, dispersion uniformity, total area of impure peaks, and appearance. Flunarizine hydrochloride and Ophiorrhiza japonica extract have significant synergistic effect; the drug has little toxic and side effects and has total cure rate of up to 97.5%.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a medicine for reducing the side effect of flunarizine hydrochloride and treating angioneurotic headache. Background technique [0002] Angioneurotic headache, or migraine, is a type of episodic headache caused by vasomotor dysfunction. It is more common in women, most of them begin in adolescence, and there is often a family history. There are often certain triggers before the onset, such as menstrual cramps, emotional agitation, and fatigue. Angioneurotic headache, the nature of the headache includes throbbing pain, stabbing pain, stabbing pain, pulsating pain, distending pain, etc., and the severe case has a headache like splitting. Most patients are accompanied by symptoms such as dizziness, insomnia, upset, and memory loss. Severe cases are accompanied by nausea, vomiting, sore eyes, tearing, and blurred vision. Some patients have attacks once in several days or months,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/74A61K9/20A61K47/38A61K47/36A61K47/26A61K47/04A61P25/06A61K31/495
CPCA61K9/2009A61K9/2018A61K9/2054A61K9/2059A61K31/495A61K36/74A61P25/06A61K2300/00
Inventor 殷德年
Owner LINYI DELIKANG MEDICAL REHABILITATION EQUIP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com